RACGAP1

Across TCGA pan-cancer cohorts, RACGAP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RACGAP1 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RACGAP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RACGAP1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where RACGAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.267	0.737	.007	37	view →
LUAD	DFS	Tertile	All	0.467	1.000	.001	21	view →
CCRCC	OS	Median	II,III,IV	0.579	1.000	.011	20	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
GBM	DFS	Tertile	All	0.626	0.851	.006	4	view →
LSCC	DFS	Quartile	All	0.798	0.550	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RACGAP1–PDAC (DFS)

Open the PDAC breakdown →